https://respiratorytrials.org/ A curated, verified index of the trials that underpin respiratory practice. Every citation is checked against PubMed. en-GB Thu, 06 Aug 2026 08:23:32 +0000 https://respiratorytrials.org/trial/teton-2/ https://respiratorytrials.org/trial/teton-2/ Interstitial lung disease Inhaled treprostinil slowed FVC decline in IPF, in patients mostly already on antifibrotics https://respiratorytrials.org/trial/abra/ https://respiratorytrials.org/trial/abra/ Asthma A single dose of benralizumab at the time of an eosinophilic exacerbation beat prednisolone https://respiratorytrials.org/trial/aspen/ https://respiratorytrials.org/trial/aspen/ Bronchiectasis Brensocatib cut exacerbations by about 20% — the first drug licensed specifically for bronchiectasis https://respiratorytrials.org/trial/clear/ https://respiratorytrials.org/trial/clear/ Bronchiectasis Neither hypertonic saline nor carbocisteine reduced exacerbations in bronchiectasis https://respiratorytrials.org/trial/fibroneer-ild/ https://respiratorytrials.org/trial/fibroneer-ild/ Interstitial lung disease Nerandomilast slowed FVC decline in progressive pulmonary fibrosis, including on top of nintedanib https://respiratorytrials.org/trial/fibroneer-ipf/ https://respiratorytrials.org/trial/fibroneer-ipf/ Interstitial lung disease Nerandomilast slowed FVC decline on top of existing antifibrotics — the first genuinely additive agent in IPF https://respiratorytrials.org/trial/matinee/ https://respiratorytrials.org/trial/matinee/ COPD Mepolizumab reduced exacerbations by 21% in eosinophilic COPD on triple therapy, without improving symptoms https://respiratorytrials.org/trial/peerless/ https://respiratorytrials.org/trial/peerless/ Pulmonary embolism Mechanical thrombectomy beat catheter-directed lysis on a composite driven by less ICU use, with no mortality difference https://respiratorytrials.org/trial/predmeth/ https://respiratorytrials.org/trial/predmeth/ Interstitial lung disease Methotrexate matched prednisone as first-line treatment for pulmonary sarcoidosis, with a different side-effect profile https://respiratorytrials.org/trial/renove/ https://respiratorytrials.org/trial/renove/ Pulmonary embolism Reduced-dose anticoagulation failed formal non-inferiority for recurrence but bled much less https://respiratorytrials.org/trial/skyline/ https://respiratorytrials.org/trial/skyline/ Cystic fibrosis The once-daily triple matched the twice-daily standard on lung function https://respiratorytrials.org/trial/zenith/ https://respiratorytrials.org/trial/zenith/ Pulmonary hypertension Sotatercept cut death, transplant or hospitalisation by three quarters in high-risk PAH https://respiratorytrials.org/trial/promis/ https://respiratorytrials.org/trial/promis/ Bronchiectasis Inhaled colistimethate reduced exacerbations in one trial and not in its replicate https://respiratorytrials.org/trial/redox/ https://respiratorytrials.org/trial/redox/ COPD 24 hours a day of oxygen was no better than 15 in severe hypoxaemia https://respiratorytrials.org/trial/surmount-osa/ https://respiratorytrials.org/trial/surmount-osa/ Sleep medicine Tirzepatide halved the apnoea-hypopnoea index in obese patients with OSA https://respiratorytrials.org/trial/swift/ https://respiratorytrials.org/trial/swift/ Asthma Two injections a year roughly halved exacerbations in eosinophilic severe asthma https://respiratorytrials.org/trial/boreas/ https://respiratorytrials.org/trial/boreas/ COPD Dupilumab cut exacerbations by 30% in eosinophilic COPD already on triple therapy https://respiratorytrials.org/trial/calgb-140503/ https://respiratorytrials.org/trial/calgb-140503/ Lung cancer Sublobar resection matched lobectomy for small peripheral node-negative lung cancers https://respiratorytrials.org/trial/cape-cod/ https://respiratorytrials.org/trial/cape-cod/ Pneumonia Hydrocortisone roughly halved 28-day mortality in severe community-acquired pneumonia https://respiratorytrials.org/trial/enhance/ https://respiratorytrials.org/trial/enhance/ COPD Ensifentrine improved lung function in both replicate trials and reduced exacerbations, with placebo-level tolerability https://respiratorytrials.org/trial/ever-ild/ https://respiratorytrials.org/trial/ever-ild/ Interstitial lung disease Adding rituximab to mycophenolate improved lung function in NSIP-pattern ILD, with more viral infection https://respiratorytrials.org/trial/simplify/ https://respiratorytrials.org/trial/simplify/ Cystic fibrosis Patients on triple modulator therapy could stop hypertonic saline or dornase alfa without losing lung function https://respiratorytrials.org/trial/epic-hr/ https://respiratorytrials.org/trial/epic-hr/ COVID-19 Nirmatrelvir-ritonavir cut hospitalisation or death by 89% in unvaccinated high-risk outpatients https://respiratorytrials.org/trial/mandala/ https://respiratorytrials.org/trial/mandala/ Asthma Adding budesonide to the albuterol reliever cut severe exacerbations by a quarter https://respiratorytrials.org/trial/tip-ex/ https://respiratorytrials.org/trial/tip-ex/ Ventilation & weaning Pressure support and T-piece breathing trials produced the same ventilator-free days https://respiratorytrials.org/trial/increase/ https://respiratorytrials.org/trial/increase/ Pulmonary hypertension Inhaled treprostinil improved walk distance in PH due to interstitial lung disease https://respiratorytrials.org/trial/navigator/ https://respiratorytrials.org/trial/navigator/ Asthma Tezepelumab halved exacerbations in severe asthma, including in patients with low eosinophils https://respiratorytrials.org/trial/recovery-dexamethasone/ https://respiratorytrials.org/trial/recovery-dexamethasone/ COVID-19 Dexamethasone reduced mortality in COVID-19 patients needing oxygen, and not in those who did not https://respiratorytrials.org/trial/remap-cap-il-6/ https://respiratorytrials.org/trial/remap-cap-il-6/ COVID-19 IL-6 receptor blockade improved organ support-free days and survival in critical COVID-19 https://respiratorytrials.org/trial/remap-cap-anticoagulation/ https://respiratorytrials.org/trial/remap-cap-anticoagulation/ COVID-19 Full-dose anticoagulation did not help critically ill COVID-19 patients https://respiratorytrials.org/trial/actt-1/ https://respiratorytrials.org/trial/actt-1/ COVID-19 Remdesivir shortened time to recovery by five days without a clear mortality benefit https://respiratorytrials.org/trial/dexa-ards/ https://respiratorytrials.org/trial/dexa-ards/ ARDS Dexamethasone reduced ventilator days and mortality in established moderate-to-severe ARDS https://respiratorytrials.org/trial/ethos/ https://respiratorytrials.org/trial/ethos/ COPD Triple therapy beat both dual therapies, and the lower steroid dose worked as well as the higher https://respiratorytrials.org/trial/loco2/ https://respiratorytrials.org/trial/loco2/ ARDS Targeting a low PaO2 in ARDS did not help and raised safety concerns https://respiratorytrials.org/trial/nelson/ https://respiratorytrials.org/trial/nelson/ Lung cancer Volume CT screening reduced lung cancer mortality with a 2.1% referral rate https://respiratorytrials.org/trial/psp/ https://respiratorytrials.org/trial/psp/ Pleural disease Most primary spontaneous pneumothoraces resolved without any intervention, though the non-inferiority result is fragile https://respiratorytrials.org/trial/rampp/ https://respiratorytrials.org/trial/rampp/ Pleural disease Ambulatory devices sent most patients home the same day, but caused more adverse events https://respiratorytrials.org/trial/tapps/ https://respiratorytrials.org/trial/tapps/ Pleural disease Talc poudrage at thoracoscopy was no better than talc slurry down a chest drain https://respiratorytrials.org/trial/inbuild/ https://respiratorytrials.org/trial/inbuild/ Interstitial lung disease Nintedanib slowed FVC decline across progressive fibrosing ILD, whatever the underlying diagnosis https://respiratorytrials.org/trial/pleural-manometry/ https://respiratorytrials.org/trial/pleural-manometry/ Pleural disease Manometry during large-volume drainage did not reduce chest discomfort https://respiratorytrials.org/trial/rose/ https://respiratorytrials.org/trial/rose/ ARDS Routine early paralysis added nothing when the comparator was lighter sedation https://respiratorytrials.org/trial/senscis/ https://respiratorytrials.org/trial/senscis/ Interstitial lung disease Nintedanib slowed lung function decline in scleroderma ILD, but the result is fragile and skin disease was unchanged https://respiratorytrials.org/trial/tec/ https://respiratorytrials.org/trial/tec/ Smoking cessation E-cigarettes nearly doubled one-year quit rates compared with nicotine replacement https://respiratorytrials.org/trial/vx17-445-102/ https://respiratorytrials.org/trial/vx17-445-102/ Cystic fibrosis Triple modulator therapy gave a 14-point FEV1 gain to the 90% of CF patients with a single Phe508del allele https://respiratorytrials.org/trial/eolia/ https://respiratorytrials.org/trial/eolia/ ARDS Immediate ECMO did not significantly beat conventional ventilation with ECMO held in reserve https://respiratorytrials.org/trial/impact/ https://respiratorytrials.org/trial/impact/ COPD Triple therapy reduced exacerbations versus either dual therapy, at the cost of more pneumonia https://respiratorytrials.org/trial/sunset/ https://respiratorytrials.org/trial/sunset/ COPD Stopping inhaled steroids cost a little lung function but no extra exacerbations, except in eosinophilic patients https://respiratorytrials.org/trial/sygma-1/ https://respiratorytrials.org/trial/sygma-1/ Asthma As-needed ICS/formoterol beat reliever alone on symptoms and exacerbations, but lost to daily ICS on symptom control https://respiratorytrials.org/trial/sygma-2/ https://respiratorytrials.org/trial/sygma-2/ Asthma As-needed ICS/formoterol matched daily ICS for exacerbations on a quarter of the steroid dose https://respiratorytrials.org/trial/tribute/ https://respiratorytrials.org/trial/tribute/ COPD Extrafine triple therapy modestly reduced exacerbations versus dual bronchodilation, without excess pneumonia https://respiratorytrials.org/trial/amazes/ https://respiratorytrials.org/trial/amazes/ Asthma Azithromycin cut asthma exacerbations by 41% and improved quality of life, at the cost of diarrhoea https://respiratorytrials.org/trial/ample/ https://respiratorytrials.org/trial/ample/ Pleural disease Indwelling pleural catheters kept patients out of hospital more than talc pleurodesis https://respiratorytrials.org/trial/art/ https://respiratorytrials.org/trial/art/ ARDS Aggressive recruitment with titrated PEEP increased mortality https://respiratorytrials.org/trial/flame/ https://respiratorytrials.org/trial/flame/ COPD Dual bronchodilation beat LABA/ICS for exacerbation prevention, with less pneumonia https://respiratorytrials.org/trial/lott/ https://respiratorytrials.org/trial/lott/ COPD Oxygen for moderate desaturation did nothing for survival, admissions, or quality of life https://respiratorytrials.org/trial/save/ https://respiratorytrials.org/trial/save/ Sleep medicine CPAP did not prevent cardiovascular events, though it treated the apnoea and improved symptoms https://respiratorytrials.org/trial/ambition/ https://respiratorytrials.org/trial/ambition/ Pulmonary hypertension Starting two vasodilators at once halved clinical failure compared with either alone https://respiratorytrials.org/trial/florali/ https://respiratorytrials.org/trial/florali/ Ventilation & weaning High-flow oxygen did not reduce intubation but was associated with lower 90-day mortality https://respiratorytrials.org/trial/prepic2/ https://respiratorytrials.org/trial/prepic2/ Pulmonary embolism Adding a retrievable IVC filter to anticoagulation prevented nothing https://respiratorytrials.org/trial/react/ https://respiratorytrials.org/trial/react/ COPD Roflumilast missed its primary endpoint by a whisker and hit it on the sensitivity analysis https://respiratorytrials.org/trial/serve-hf/ https://respiratorytrials.org/trial/serve-hf/ Sleep medicine Adaptive servo-ventilation abolished the central apnoeas and increased mortality https://respiratorytrials.org/trial/ascend/ https://respiratorytrials.org/trial/ascend/ Interstitial lung disease Pirfenidone slowed FVC decline and improved progression-free survival in IPF https://respiratorytrials.org/trial/inpulsis/ https://respiratorytrials.org/trial/inpulsis/ Interstitial lung disease Nintedanib roughly halved the annual rate of FVC decline in IPF, at the cost of diarrhoea https://respiratorytrials.org/trial/peitho/ https://respiratorytrials.org/trial/peitho/ Pulmonary embolism Thrombolysis prevented decompensation in intermediate-risk PE but caused major bleeding and stroke https://respiratorytrials.org/trial/star/ https://respiratorytrials.org/trial/star/ Sleep medicine Hypoglossal nerve stimulation cut the AHI by two thirds — in an uncontrolled cohort https://respiratorytrials.org/trial/bat/ https://respiratorytrials.org/trial/bat/ Bronchiectasis Maintenance azithromycin roughly halved the proportion of patients having any exacerbation https://respiratorytrials.org/trial/proseva/ https://respiratorytrials.org/trial/proseva/ ARDS Prone positioning halved mortality in severe ARDS https://respiratorytrials.org/trial/barbe-2012/ https://respiratorytrials.org/trial/barbe-2012/ Sleep medicine CPAP did not significantly reduce incident hypertension or cardiovascular events in non-sleepy OSA https://respiratorytrials.org/trial/primotina-asthma/ https://respiratorytrials.org/trial/primotina-asthma/ Asthma Adding tiotropium to ICS/LABA gave modest bronchodilation and 21% fewer severe exacerbations https://respiratorytrials.org/trial/macro/ https://respiratorytrials.org/trial/macro/ COPD Daily azithromycin for a year cut exacerbations and improved quality of life, at the cost of hearing loss and resistance concerns https://respiratorytrials.org/trial/mist2/ https://respiratorytrials.org/trial/mist2/ Pleural disease Combined t-PA and DNase improved drainage and cut surgical referral; neither drug worked alone https://respiratorytrials.org/trial/nlst/ https://respiratorytrials.org/trial/nlst/ Lung cancer Low-dose CT screening reduced lung cancer mortality — at the cost of a 96% false-positive rate https://respiratorytrials.org/trial/poet-copd/ https://respiratorytrials.org/trial/poet-copd/ COPD Tiotropium prevented exacerbations better than salmeterol https://respiratorytrials.org/trial/strive/ https://respiratorytrials.org/trial/strive/ Cystic fibrosis Ivacaftor produced a 10-point FEV1 gain in G551D cystic fibrosis — the first drug to correct the basic defect https://respiratorytrials.org/trial/acurasys/ https://respiratorytrials.org/trial/acurasys/ ARDS Early cisatracurium improved adjusted 90-day survival in severe ARDS https://respiratorytrials.org/trial/cesar/ https://respiratorytrials.org/trial/cesar/ ARDS Referral to an ECMO centre improved 6-month survival without disability in severe respiratory failure https://respiratorytrials.org/trial/3cpo/ https://respiratorytrials.org/trial/3cpo/ Ventilation & weaning Non-invasive ventilation made patients with pulmonary oedema feel better faster without saving lives https://respiratorytrials.org/trial/wake-up-and-breathe/ https://respiratorytrials.org/trial/wake-up-and-breathe/ Ventilation & weaning Pairing daily sedation interruption with a breathing trial got patients off ventilators sooner and improved survival https://respiratorytrials.org/trial/torch/ https://respiratorytrials.org/trial/torch/ COPD Salmeterol/fluticasone narrowly missed a mortality benefit but reduced exacerbations, at the cost of more pneumonia https://respiratorytrials.org/trial/lung-health-study/ https://respiratorytrials.org/trial/lung-health-study/ Smoking cessation A cessation programme that worked for one in five participants still reduced all-cause mortality over 14.5 years https://respiratorytrials.org/trial/nett/ https://respiratorytrials.org/trial/nett/ COPD No overall survival benefit, but a real one for upper-lobe emphysema with low exercise capacity https://respiratorytrials.org/trial/pneuma/ https://respiratorytrials.org/trial/pneuma/ Pneumonia Eight days of antibiotics matched fifteen for ventilator-associated pneumonia, except in non-fermenting gram-negatives https://respiratorytrials.org/trial/mappet-3/ https://respiratorytrials.org/trial/mappet-3/ Pulmonary embolism Alteplase reduced treatment escalation in submassive PE, but the benefit was almost entirely in that soft endpoint https://respiratorytrials.org/trial/arma/ https://respiratorytrials.org/trial/arma/ ARDS Ventilating at 6 mL/kg instead of 12 cut ARDS mortality from 40% to 31% https://respiratorytrials.org/trial/rhdnase-in-bronchiectasis/ https://respiratorytrials.org/trial/rhdnase-in-bronchiectasis/ Bronchiectasis DNase made idiopathic bronchiectasis worse, not better https://respiratorytrials.org/trial/brochard-1995/ https://respiratorytrials.org/trial/brochard-1995/ Ventilation & weaning Non-invasive ventilation cut intubation, length of stay and mortality in COPD exacerbations https://respiratorytrials.org/trial/anthonisen-1987/ https://respiratorytrials.org/trial/anthonisen-1987/ COPD Antibiotics helped exacerbations defined by increased dyspnoea, sputum volume and purulence https://respiratorytrials.org/trial/mrc-oxygen/ https://respiratorytrials.org/trial/mrc-oxygen/ COPD Domiciliary oxygen for at least 15 hours a day improved survival in hypoxaemic cor pulmonale https://respiratorytrials.org/trial/nott/ https://respiratorytrials.org/trial/nott/ COPD Continuous oxygen halved mortality compared with nocturnal-only oxygen in hypoxaemic COPD